|Articles|September 2, 2001
- Pharmaceutical Technology-09-02-2001
- Volume 25
- Issue 9
Replacing the Animal Component in SerumEvaluating Raw Materials for Inclusion in Optimized Hybridoma Media
With the scarcity of CGMP facilities spurring a production crisis, manufacturers need to optimize their processes and formulations for individual hybridoma cell lines and production systems.
Advertisement
Articles in this issue
almost 25 years ago
Six Sigma Can Give Contractors a Quality Advantagealmost 25 years ago
Industry Changes OTC Labels as Deadline Approachesalmost 25 years ago
A Report of the PQRI Workshop on Blend Uniformityalmost 25 years ago
Are You Ready for Global Manufacturing?almost 25 years ago
Pharmaceutical Coverage and Costsalmost 25 years ago
Outsourcing OutlookAdvertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA Activity Round Up – July 2026
2
Midyear 2026 Check-In: Agentic AI Cuts Deviation Investigations by 50%
3
Can Governance-by-Design Make AI Compliant in Pharma? (Part II)
4
From Predictions to Reality: Mike Stenberg Assesses Pharma Manufacturing's First Half of 2026
5